Statements (56)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
pharmaceutical drug
|
| gptkbp:activeDuring |
budesonide
formoterol fumarate |
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:availableIn |
multiple countries
|
| gptkbp:brand |
gptkb:Symbicort_Turbuhaler
Symbicort pMDI |
| gptkbp:clinicalTrials |
Phase III
maintenance therapy rescue therapy |
| gptkbp:contains |
budesonide
formoterol |
| gptkbp:contraindication |
dizziness
sleep disturbances cough increased heart rate throat irritation hypersensitivity to budesonide hypersensitivity to formoterol |
| gptkbp:dosageForm |
dry powder inhaler
metered-dose inhaler |
| gptkbp:drugInterdiction |
gptkb:MAO_inhibitors
excreted in urine metabolized in the liver prescription only diuretics beta-blockers high bioavailability rapid absorption |
| gptkbp:formulation |
combination therapy
|
| gptkbp:hasPopulation |
adults
children over 12 years |
| gptkbp:healthcare |
important for effectiveness
recognizing side effects how to use inhaler importance of regular use |
| https://www.w3.org/2000/01/rdf-schema#label |
Symbicort
|
| gptkbp:impact |
as prescribed by a doctor
|
| gptkbp:issuedBy |
inhalation aerosol
|
| gptkbp:lastProduced |
2006
|
| gptkbp:manufacturer |
gptkb:AstraZeneca
|
| gptkbp:regulatoryCompliance |
approved_in_Australia
approved_in_Canada approved_in_Europe approved_in_Japan |
| gptkbp:sideEffect |
headache
nausea palpitations tremor thrush |
| gptkbp:storage |
room temperature
protect from moisture |
| gptkbp:triggerType |
anti-inflammatory
bronchodilator |
| gptkbp:usedFor |
asthma
chronic obstructive pulmonary disease (COPD) |